2025-05-17
Recently, researchers found that after 18 months of treatment with evolocumab, patients with coronary heart disease did not have a significant change in the total plaque volume of the patients, but the composition of the plaques changed significantly. There was a significant reduction in the volume of non-calcified plaques and a significant reduction in low-attenuation non-calcified plaques, a type of plaque that is more prone to breakage. At the same time, the volume of calcified plaques increased, in addition to a significant decrease in coronary microcalcification activity (a marker of inflammation) and a decrease in the target-to-background ratio of the lesion site. These results suggest that evolocumab not only lowers cholesterol levels in the body, but also reduces the inflammatory activity of plaques, thereby reducing the risk of heart attack.
